| Name | Other names | Mechanism of action | Indication | Type | Status | Company |
|---|---|---|---|---|---|---|
| ACP-044 | CT-044 | Reactive species decomposition accelerant preventing hyper-activation of TRPA1 | Acute post-operative, chronic neuropathic pain | Phase I | ACADIA Pharmaceuticals | |
| AM-6120, AM-8145, AM-0422 | Nav1.7 inhibitor | Peptide | Discovery | Amgen | ||
| AP30663 | KCa inhibitor | Atrial fibrillation | Phase I/II | Acesion Pharma | ||
| AP-325 | Positive allosteric modulator of GABA-A | Neuropathic pain | Small Molecule | Phase IIa | Algiax Pharmaceuticals |
|
| ARO-ENaC | ENAC downregulation | Cystic fibrosis | RNAi therapeutic | Phase I/IIa | Arrowhead Pharmaceuticals |
|
| ASN008 | Na+ channel blocker | Pruritus, atopic dermatitis, pain | Phase IIa | Asana BioSciences | ||
| ASN009 | P2X3 antagonist | Cough | Preclinical | Asana BioSciences | ||
| ASP-0819 | KCa3.1 activator | Fibromyalgia | Phase II | Astellas Pharma | ||
| AUT00201 | Modulator of Kv3 channels | Schizophrenia, hearing disorders | Phase I | Autifony Therapeutics | ||
| Auxora | CM4620-IE | CRAC inhibitor | Severe COVID-19 pneumonia, Viral pneumonia, Acute pancreatitis | Small Molecule | Phase II | CalciMedica |
| AV-101 | 4-Cl-KYN | NMDAR antagonist | CNS disorders | Preclinical | VistaGen Therapeutics |
|
| AXS-05 | NMDAR antagonist | Major Depressive Disorder, Alzheimer’s Disease agitation, and Smoking Cessation | Small Molecule | Phase III | Axsome Therapeutics |
|
| BAY-1817080 | P2X3 inhibitor | Endometriosis and persistent chronic cough | Phase I | Bayer | ||
| BAY-1902607 | P2X3 inhibitor | Persistent chronic cough | Phase II | Bayer | ||
| BAY-2253651 | TASK inhibitor | Obstructive sleep apnoea | Phase II | Bayer | ||
| BIIB093 | SUR1-TRPM4 blocker | Brain Contusion | Small Molecule | Phase II | Biogen | |
| BIIB095 | Nav1.7 inhibitor | Neuropathic pain | Small Molecule | Phase I | Biogen | |
| BIIB104 | PF-04958242 | AMPAR activator | Cognitive impairment associated with schizophrenia | Phase IIa | Biogen | |
| BIL010t | nfP2X7 | Skin cancer | Antibody | Phase I | Biosceptre | |
| BIL06v | nfP2X7 | Skin cancer | Peptide vaccine | Phase I | Biosceptre | |
| BLU-5937 | P2X3 antagonist | Refractory chronic cough | Phase IIb | BELLUS Health | ||
| BNC-210 | alpha7 nAChRs antagonist | Agitation, post-traumatic stress disorder, generalised anxiety disorder | Phase II | Bionomics | ||
| CAD-1883 | KCa activator | Ataxia or essential tremors | Phase I/II | Cadent Therapeutics | ||
| CAD-9303 | NMDAR positive allosteric modulator | Schizophrenia | Phase I | Cadent Therapeutics |
||
| CC 8464 | ASP 1807 | Nav1.7 antagonist | Neuropathic and inflammatory pain | Small Molecule | Phase I | Chromocell/Astellas Pharma |
| CVL-865 | Positive allosteric modulator of alpha-2/3/5 subunits of the GABA-A | Drug-resistant focal onset epilepsy | Phase I/II | Cerevel Therapeutics | ||
| CVL-865 | Positive allosteric modulator of alpha-2/3/5 subunits of the GABA-A | Acute anxiety | Phase I | Cerevel Therapeutics | ||
| CX-8998 | T-type calcium channel modulator | Absence epilepsy, essential tremor | Phase II | Cavion | ||
| Dalazatide | ShK-186 | Kv1.3 inhibitor | Myositis, Psoriasis | Synthetic peptide | Phase II | Kv1.3 Therapeutics |
| DSP-2230 | NaV1.7 and NaV1.8 inhibitor | Neuropathic pain | Small Molecule | Phase I | AlphaNavi Pharma | |
| DSP-3905 | NaV1.7 inhibitor | Neuropathic pain | Small Molecule | Phase I | Sunovion Pharmaceuticals | |
| ENX-101 | sub-type selective GABA-A modulator | Diseases of the nervous system | Preclinical | Engrail Therapeutics | ||
| ETD001 | ENaC blocker | Respiratory diseases | Preclinical | Enterprise Therapeutics | ||
| ETD002 | TMEM16A potentiator | Cystic fibrosis | Phase I | Enterprise Therapeutics | ||
| Evenamide | Nav blocker | Schizophrenia | Phase II | Newron Pharmaceuticals | ||
| Evt201 | GABAA receptor PAM | Insomnia | Phase II | Evotec | ||
| FX301 | Funapide | Nav1.7 inhibitor | Acute post-operative pain | Preclinical | Flexion | |
| Galicaftor | ABBV-2222 | CFTR | Cystic fibrosis | Phase II | AbbVie | |
| GFB-887 | TRPC5 inhibitor | Focal segmental glomerulosclerosis, diabetic nephropathy | Phase I/II | Goldfinch Bio | ||
| Granexin gel | alphaCT1, a peptide mimetic of the Cx43 carboxyl terminus | Cutaneous radiation injury, Diabetic foot and venous leg ulcers | Synthetic peptide | Phase III | FirstString Research | |
| GRC 17536 | TRPA1 antagonist | Painful diabetic neuropathy | Phase II | Glenmark | ||
| GSK-2798745 | TRPV4 inhibitor | Heart failure | Phase II | GlaxoSmithKline | ||
| Halneuron | Tetrodotoxin | Nav blocker | Severe neuropathic pain, cancer related pain | Small Molecule | Phase III | Wex Pharmaceuticals |
| HBI-3000 | Multi-channel inhibitor | Atrial fibrillation | Phase I | HUYA Bioscience International | ||
| JNJ-55308942 | P2X7 inhibitor | Neuroinflammation and anhedonia | Phase I | Johnson & Johnson | ||
| KB-3061 | Kv7 modulator | KCNQ2 epileptic encephalopathy | Preclinical | Knopp Biosciences | ||
| KCP-506 | alpha9alpha10 nAChR antagonist | Chronic pain | Phase I | Kineta | ||
| Kv7 modulator | Kv7 modulator | Neuropathic pain, hearing disorders, ALS | Discovery | Knopp Biosciences | ||
| LUNAR-CF | CFTR upregulation | Cystic fibrosis | mRNA therapeutic | Preclinical | Arcturus Therapeutics |
|
| MIJ821 | CAD-9271 | NMDAR negative allosteric modulator | Depression | Phase II | Novartis |
|
| MK-7264 | Gefapixant | P2X3 antagonist | Chronic cough | Small Molecule | Phase III | Merck, Roche |
| MRT5005 | CFTR upregulation | Cystic fibrosis | mRNA therapeutic | Phase I/II | Translate Bio |
|
| NBI-1065845 | TAK-653 | AMPAR activator | Depression | Phase II | Neurocrine Biosciences, Takeda | |
| NBI-827104 | ACT-709478 | T-type calcium channel blocker | Pediatric epilepsy | Phase I/II | Neurocrine Biosciences, Idorsia | |
| NBI-921352 | XEN901 | Nav1.6 inhibitor | Epilepsy | Small Molecule | Phase I/II | Neurocrine Biosciences, Xenon |
| NMD670 | Skeletal muscle specific inhibitor of ClC-1 | Myasthenia gravis | Small Molecule | Phase I/IIa | NMD Pharma | |
| NOC-100 | NTX-1175 | Charged sodium channel blocker | Chronic and acute cough | Small Molecule | Phase I | Nocion Therapeutics |
| OV101 | Gaboxadol | GABA-A agonist | Fragile X syndrome, Angelman syndrome | Small Molecule | Phase II-III | Ovid Therapeutics |
| P-1037 | VX-371 | ENaC inhibitor | Pulmonary diseases | Phase II | Parion Sciences, Vertex Pharmaceuticals | |
| P-1055 | VX-551 | ENaC inhibitor | Pulmonary diseases | Preclinical | Parion Sciences, Vertex Pharmaceuticals | |
| P-321 | ENaC inhibitor | Dry eye disease | Phase II | Parion Sciences, Takeda | ||
| P2X4 inhibitor | P2X4 inhibitor | Endometriosis | Phase I | Bayer | ||
| P2X7 MAB | P2X7 monoclonal antibody | Autoimmune disorders | Antibody | Preclinical | Integral Molecular | |
| PRAX-114 | GABA-A positive allosteric modulator | Major depressive disorder, perimenopausal depression | Small Molecule | Phase II | Praxis Precision Medicines | |
| PRAX-944 | T-type calcium channel blocker | Essential tremor | Small Molecule | Phase II | Praxis Precision Medicines | |
| PRAX-562 | Pediatric epilepsy, adult cephalgia | Small Molecule | Phase I | Praxis Precision Medicines | ||
| PRAX-020/021 | Genetic epilepsies | Preclinical | Praxis Precision Medicines | |||
| PRAX-222 | Genetic epilepsies | Preclinical | Praxis Precision Medicines | |||
| Ralfinamide | Nav blocker, Cav2.2 blocker | Neuropathic pain | Phase II | Newron Pharmaceuticals | ||
| Resiniferatoxin | TRPV1 agonist | Cancer pain | Small Molecule | Phase I | Sorrento Therapeutics | |
| RG-7816 | GABA-A receptor alpha5 subunit-targeting NAM | Autism spectrum disorder | Phase I | Roche | ||
| S-600918 | P2X3 antagonist | Refractory chronic cough | Phase IIb | Shionogi | ||
| SAN711 | GABAA alpha3 modulator | Neuropathic pain disorders | Preclinical | Saniona | ||
| SAN903 | KCa3.1 inhibitor | Rare inflammatory/fibrotic diseases, hereditary xerocytosis | Preclinical | Saniona | ||
| SAGE-217 | Zuranolon, S-812217 | GABA-A positive allosteric modulator | Major depression | Small Molecule | Phase II | Sage Therapeutics, Shionogi |
| SAGE-324 | GABA-A receptor PAM | Essential tremor and Parkinson disease | Phase I | Sage Therapeutics | ||
| SAGE-689 | GABA-A modulator | GABA hypofunction | Preclinical | Sage Therapeutics | ||
| SAGE-718 | NMDAR activator | NMDAR hypofunction | Phase I | Sage Therapeutics | ||
| SAGE-904 | NMDAR modulator | NMDAR hypofunction | Preclinical | Sage Therapeutics | ||
| Senicapoc | KCa3.1 inhibitor | Hereditary xerocytosis and Alzheimer disease | Phase I | SpringWorks Therapeutics/ University of California, Davis |
||
| SOR-C13 | TRPV6 inhibitor | Solid tumor cancer | Synthetic peptide | Phase Ib | Soricimed Biopharma | |
| ST-2427 | Nav1.7 inhibitor | Post-operative pain | Small Molecule | IND | SiteOne Therapeutics | |
| STK-001 | Upregulates Nav1.1 protein expression | Dravet syndrome | Antisense oligonucleotide | Phase I/IIa | Stoke Therapeutics | |
| TRPC4 and TRPC5 inhibitor | TRPC4 and TRPC5 inhibitor | Anxiety disorder and depression | Phase I | Hydra/Boehringer Ingelheim | ||
| VX-150 | Nav1.8 inhibitor | Acute and neuropathic pain | Small Molecule | Phase II | Vertex Pharmaceuticals | |
| XEN007 | Flunarizine | Cav2.1 modulator | Migraine and other neurological disorders | Small Molecule | Phase I | Xenon |
| XEN1101 | Kv7 modulator | Epilepsy | Phase II | Xenon | ||
| XEN496 | Retigabine | Kv7 modulator | KCNQ2 and pediatric epilepsy | Phase II | Xenon | |
| XEN-D0501 | TRPV1 antagonist | Type 2 diabetes | Phase II | Pila Pharma |